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Abstract Lenalidomide is a lead therapeutic in multiple
myeloma and deletion 5q myelodysplastic syndromes and
shows promising activities in other hematologic malig-
nancies. This article presents a comprehensive review of
the clinical pharmacokinetics and pharmacodynamics of
lenalidomide. Oral lenalidomide is rapidly and highly
absorbed ([90 % of dose) under fasting conditions. Food
affects oral absorption, reducing area under the concen-
tration–time curve (AUC) by 20 % and maximum con-
centration (Cmax) by 50 %. The increase in AUC and Cmax
is dose proportional, and interindividual variability in
plasma exposure is low to moderate. Lenalidomide dis-
tributes into semen but is undetectable 3 days after stop-
ping treatment. Biotransformation of lenalidomide in
humans includes chiral inversion, trivial hydroxylation,
and slow non-enzymatic hydrolysis. Approximately 82 %
of an oral dose is excreted as lenalidomide in urine within
24 h. Lenalidomide has a short half-life (3–4 h) and does
not accumulate in plasma upon repeated dosing. Its phar-
macokinetics are consistent across patient populations,
regardless of the type of hematologic malignancy. Renal
function is the only important factor affecting lenalidomide
plasma exposure. Lenalidomide has no QT prolongation
risk at approved doses, and higher plasma exposure to
lenalidomide is associated with increased risk of neu-
tropenia and thrombocytopenia. Despite being a weak
substrate of P-glycoprotein (P-gp) in vitro, lenalidomide
does not have clinically significant pharmacokinetic inter-
actions with P-gp substrates/inhibitors in controlled
studies. The AUC-matched dose adjustment is recom-
mended for patients with renal impairment at the start of
therapy. No dose adjustment for lenalidomide is needed on
the basis of age, ethnicity, mild hepatic impairment, or
drug–drug interactions.
Key Points
Lenalidomide represents the standard of care for
treating multiple myeloma and deletion 5q
myelodysplastic syndromes.
This is a review of the pharmacokinetics,
pharmacodynamics, exposure–response
relationships, and assessment of potential drug–drug
interactions of lenalidomide in various hematologic
malignancies.
The starting dose of lenalidomide must be adjusted
according to renal function.
1 Introduction
Lenalidomide is a chemical analog of thalidomide, with
antineoplastic, antiangiogenic, pro-erythropoietic, and
immunomodulatory properties [1–3]. It binds to an E3
ubiquitin ligase complex protein, cereblon, modulating its
downstream effects [4–6]. This interaction was shown to be
associated with antitumor and immunomodulatory proper-
ties of lenalidomide [3, 6, 7].
Clinical efficacy has been demonstrated for lenalido-
mide in the treatment of hematologic malignancies [8–13].
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It is approved in combination with dexamethasone for the
treatment of multiple myeloma (MM) and as monotherapy
for the treatment of transfusion-dependent anemia due to
myelodysplastic syndromes (MDS) associated with dele-
tion 5q and relapsed or refractory mantle cell lymphoma
(MCL). Combinations of lenalidomide with small molecule
chemotherapies and novel biologic agents are being
explored in clinical trials, with several recent approvals in
the treatment of relapsed or refractory MM [14–20].
Lenalidomide has a predictable tolerability profile and
lacks the neurological side effects of thalidomide, includ-
ing sedation and neuropathy, allowing long-term adminis-
tration [2, 21, 22]. Primary adverse events (AEs) are
neutropenia and thrombocytopenia. Some AEs of
lenalidomide are more often associated with a specific
disease. For example, venous thromboembolic events are
observed more frequently in patients with MM receiving
lenalidomide/dexamethasone therapy, while tumor lysis
syndrome and tumor flare reaction are observed more fre-
quently in patients with chronic lymphocytic leukemia
(CLL) [2, 21, 22].
The recommended dose of lenalidomide is disease
specific, and the approved starting dose is lower for MDS
(10 mg/day) than for MM and MCL (25 mg/day) [23]. The
use of very low starting doses (2.5 or 5 mg) of lenalido-
mide followed by stepwise dose escalation is common in
clinical studies with CLL to minimize the risk of tumor
lysis syndrome and tumor flare [21, 24]. Importantly, the
starting dose should be adjusted according to renal function
regardless of indication [23]. Furthermore, proper dose
modifications are recommended to manage toxicities [23].
This article aims to review the available clinical data on
pharmacokinetics, pharmacodynamics, exposure–response
relationships and drug–drug interactions of lenalidomide in
various populations. This knowledge will assist clinicians
with rational dosage decisions.
2 Formulations
Lenalidomide contains an asymmetric carbon atom and is
produced as a 50:50 racemic mixture of the optically active
forms of lenalidomide, S- and R-enantiomers [23]. Com-
mercial lenalidomide products are available in the US and
EU as Revlimid hard gelatin capsules for oral adminis-
tration, with seven strengths: 2.5, 5, 7.5, 10, 15, 20, and
25 mg [23, 25]. All capsule formulations are interchange-
able for a given dose based on the results from bioequiv-
alence studies (Celgene, data on file).
Patients with dysphagia, such as the elderly and chil-
dren, have difficulty swallowing capsules. A lenalidomide
suspension formulation for these patients is currently
available in clinical studies. Because lenalidomide is a
teratogenic drug [23], opening of lenalidomide capsules
and extemporaneous compounding of lenalidomide sus-
pension or solution is not recommended. A method was
reported for tube administration of lenalidomide, in which
capsules were disintegrated in hot water to form a sus-
pension without grinding or opening them [26]. Lenalido-
mide was found to be stable in hot water at 55 C for 24 h
in the prepared suspension and was not adsorbed onto the
percutaneous endoscopic gastrostomy tube [26]. However,
it remains unknown whether tube feeding of such heated
lenalidomide suspension would achieve drug plasma
exposure similar to that of oral administration of capsules
or suspension.
3 Pharmacokinetics in Healthy Adults
3.1 Absorption
In healthy adults, lenalidomide is rapidly absorbed under
fasting conditions, with the maximum concentration (Cmax)
in plasma observed at 1 h postdose [27]. Greater than 90 %
of a dose of lenalidomide is estimated to be absorbed into
blood [28]. Consistent with the high bioavailability, the
oral bioavailability of lenalidomide is similar between
commercial capsules and an experimental oral suspension,
with mean values of both Cmax and area under the con-
centration–time curve (AUC) comparable between the two
formulations (Table 1). Lenalidomide Cmax and AUC
increase proportionally with increases in dose from 5 to
400 mg [27]. The interindividual variability for lenalido-
mide plasma exposure parameters is low to moderate in
well-controlled studies in healthy volunteers: approxi-
mately 20 % for AUC and 30 % for Cmax [29]. Coadmin-
istration with a high-fat meal reduces the extent and rate of
lenalidomide oral absorption, resulting in an approximate
20 % decrease in AUC, 50 % decrease in Cmax, and 1.6-h
delay in the time to reach Cmax (Tmax) [27].
3.2 Distribution
The ex vivo binding of lenalidomide to plasma proteins is
low: approximately 40 % in healthy volunteers [30]. The
percentage of radioactivity estimated to distribute into red
blood cells (36–44 %) approximates the mean hematocrit
value (42–43 %) following a [14C]-lenalidomide dose,
suggesting that lenalidomide, the primary radioactive
component in circulation, is distributed similarly between
cellular and plasma components of whole blood [28]. Thus,
plasma is a suitable matrix for the representation of
lenalidomide concentrations in whole blood. Apparent
volume of distribution of lenalidomide often ranges from
approximately 74–91 L in young healthy volunteers [27],
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which is greater than the volume of total body water (42 L)
after accounting for the good bioavailability ([90 %),
suggesting moderate extravascular distribution of the drug.
Because lenalidomide is a teratogenic drug, the possible
consequence of embryo-fetal exposure, absorbed from
ejaculate in females of childbearing potential through
transmission in semen from treated males is of concern. A
study was conducted in healthy males to evaluate the dis-
tribution of lenalidomide in semen [31]. Each participant
received lenalidomide 25 mg for 4 days and provided a
single semen sample at the assigned time (2, 24, 72, or
168 h) after the last dose. The mean lenalidomide con-
centration in semen was higher than the time-matched
concentration in plasma 2 and 24 h postdose (478 vs. 219
and 10 ng/mL vs. undetectable, respectively). However,
the total amount of drug presented in semen over 72 h was
very minor (\0.01 % of the dose). In addition, lenalido-
mide was not detected in semen 3 days after the last dose,
defining the starting day for ‘drug-free’ semen in healthy
males. As a precaution, males must use condoms during
sexual contact with females of reproductive potential while
taking lenalidomide and for up to 28 days after discontin-
uing lenalidomide.
3.3 Biotransformation and Metabolism
Lenalidomide undergoes rapid chiral inversion, with S-le-
nalidomide as the preferred form in humans [27]. The R/
S plasma concentration ratio stabilized within the first hour
of a racemic lenalidomide dose; R- and S-enantiomers
averaged approximately 45 and 55 % of the total circu-
lating drug [27].
In vitro studies have demonstrated that lenalidomide is
not a substrate of human cytochrome P450 (CYP) enzymes
and is not subjected to direct conjugative metabolism [32].
Lenalidomide is broken down slowly through non-enzy-
matic hydrolysis in aqueous solutions and in hepatocytes at
physiological pH, due to the hydrolytic cleavage of
lenalidomide’s glutarimide ring. Hydrolysis of lenalido-
mide also occurs in human plasma, with an in vitro half-life
of approximately 8 h [32].
Consistent with the above in vitro results, a clinical
study using [14C]-lenalidomide concluded that metabolism
contributes, to a very minor extent, to the clearance of
lenalidomide in humans [28]. The unchanged lenalidomide
was the predominant component (92 %) of the circulating
radioactivity. The remaining radioactivity consisted pri-
marily of two metabolites: 5-hydroxylenalidomide and N-
acetyl-lenalidomide, resulting from hydroxylation of the
amino-iso-indolinone moiety and N-acetylation, respec-
tively; each constituted \5 % of parent levels in circula-
tion. Neither metabolite is expected to contribute to the
therapeutic activity of lenalidomide based on the results
from in vitro pharmacological assays.
3.4 Excretion and Elimination
Provided as capsules for oral administration, lenalidomide is
eliminated predominantly through renal excretion of the
unchanged drug. In an early dose-ranging study, 65–68 % of
the administered dose was found as the unchanged drug in urine
[27]. In more recent studies, approximately 80 % of the
administered dose was consistently found in urine as unchan-





Capsule (25 mg) Suspension (25 mg)
Young adults Older adults Young adults
Age (years) 27–38 58 30
Tmax (h) 0.75 1 1
Cmax (ng/mL) 390 568 413
AUC? (h ng/mL) 1369 2091 1319
CL/F (mL/min) 301 199 318
Vz/F (L) 74 56 76
t (h) 2.8 3.3 2.8
Fe (% of dose) 74–81 84 82
CLR (mL/min) 227–251 159 259
a
References [27, 33] [30] [28]
Data are expressed as mean for age, median for Tmax, and arithmetic or geometric mean for the remaining
pharmacokinetic parameters
AUC? area under the plasma concentration–time curve from time zero to infinity, CL/F apparent total
clearance, CLR renal clearance, Cmax maximum concentration, Fe excreted in urine as unchanged drug over
24 h, t terminal half-life, Tmax time to reach Cmax, Vz/F apparent volume of distribution based on the
terminal phase
a Derived from dose, AUC?, and Fe
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within the first 8 h postdose, and urinary excretion was nearly
complete by 12 h postdose (Fig. 1). Mean renal clearance was
approximately C200 mL/min in young healthy volunteers
[27, 33], exceeding the expected rate at which the unbound
lenalidomide is filtered through the kidneys [27]. Thus, renal
excretion of lenalidomide is likely to involve active and passive
processes. However, lenalidomide renal excretion was not
saturable over an 80-fold variation in dose (5–400 mg) [27].
Provided as an oral suspension of [14C]-lenalidomide
(25 mg), total recovery of the [14C]-radioactivity from exc-
reta averaged 94.3 % of the administered dose, with mean
contributions of 90 and 4 % from urine and feces, respec-
tively [28]. The excretion was rapid, as demonstrated by a
majority (88 %) of the radioactivity being recovered within
24 h postdose. Approximately 82 % of the radioactive dose
was excreted as lenalidomide, almost exclusively via the
urinary route within the first 24 h, which is consistent with
the findings for capsule formulations.
Because of the rapid renal excretion of lenalidomide, the
plasma half-life of lenalidomide is short—generally 3 h
(Table 1). As a result, lenalidomide plasma exposure does
not accumulate upon repeated doses. In young healthy
adults, total apparent clearance of lenalidomide is approxi-
mately 300 mL/min, with 80 % accounted for by renal
clearance and 20 % by non-renal clearance [33]. Lenalido-
mide clearance tends to be lower in older healthy adults,
although renal excretion of lenalidomide is not affected [30].
4 Pharmacokinetics in Patients with Hematologic
Malignancies
The pharmacokinetics of lenalidomide have been investi-
gated in patients with various types of hematologic
malignancies, including MM, MDS, MCL, CLL, acute
myeloid leukemia (AML), adult T-cell leukemia/lym-
phoma, and peripheral T-cell lymphoma [34–42]. Most of
these diseases commonly occur later in life, at a time when
renal function is diminishing. In general, pharmacokinetic
studies for these diseases have included patients with mild
renal impairment (RI) but excluded those with moderate to
severe RI. Lenalidomide pharmacokinetics were similar
across patient populations in these studies, regardless of the
type of hematologic malignancy (Table 2). As observed in
healthy volunteers, lenalidomide displayed rapid absorp-
tion and elimination in patients, often with a median Tmax
of 1 h under fasting conditions and a mean half-life of
3–4 h. The median Tmax was longer in studies in which
food, which delays drug absorption, was not restricted prior
to dosing [38, 41, 42]. As demonstrated in Table 2, the
dose–exposure relationship remained linear across studies,
with plasma AUC and Cmax proportional to dose from 5 to
50 mg. Dose-proportional increases in AUC and Cmax were
also demonstrated in a study evaluating dose ranges in
patients with MM [29].
There were no differences in lenalidomide pharma-
cokinetics between patients of varying hematologic
malignancies and healthy volunteers if they were of
advanced age and had similar renal function (Tables 1, 2),
except for a slightly high interindividual variability for
AUC (25–60 %) [29]. Compared with young healthy vol-
unteers, patients consistently showed lower lenalidomide
clearance and thus higher AUC (?50 % or more) for the
same dose (Tables 1, 2). The reduced lenalidomide clear-
ance in patients could be partially due to less robust renal
function and thus slower excretion of lenalidomide. Inter-
estingly, lenalidomide clearance remained lower even
when patients had normal renal excretion of lenalidomide
[42]. It is possible that age-related changes in drug dispo-
sition other than renal excretion also contributed to the
decreased lenalidomide clearance in patients. The lower
apparent volume of distribution in patients (Table 2) versus
young healthy volunteers (Table 1) could be attributed to
decreased clearance because volume of distribution is
derived from the ratio of clearance to half-life in conven-
tional pharmacokinetic analyses.
Lenalidomide may have low to moderate central ner-
vous system (CNS) penetration. In a patient with menin-
geal myeloma, the plasma and cerebrospinal fluid (CSF)
concentrations of lenalidomide 1.5 h (close to plasma Tmax)
after a 25-mg dose were 1220 and 125 ng/mL, respec-
tively, resulting in a CSF-to-plasma concentration ratio of
0.1 [43]. The CSF concentration in this patient reached
therapeutic range (Table 2). In patients with recurrent/re-
fractory CNS and intraocular lymphoma, lenalidomide was
detected in ventricular CSF (0.6–7.9 ng/mL) in each of
four patients 12–15 h after a 20-mg dose but was detected








































Fig. 1 Representative plasma concentration–time and urine excre-
tion–time profiles of lenalidomide in healthy volunteers. Data are
shown as mean ± standard deviation. Adapted from Chen et al. [33]
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dose [44]. Since most of a lenalidomide dose is cleared
from the body 12 h postdose, the CSF concentration is
anticipated to be higher if measured at an earlier time point.
In line with lenalidomide penetration into CSF, improved
CNS symptoms were observed in these patients [43, 44].
5 Pharmacokinetics in Special Populations
5.1 Patients with Renal Impairment
The effect of RI on lenalidomide pharmacokinetics was
first studied in patients with non-malignant conditions [30].
In this study, RI was the result of cardiovascular and/or
endocrine disorders. Thirty patients, aged 39–76 years,
were stratified into five groups according to baseline cre-
atinine clearance (CrCl), measured by 24-h urine collec-
tion: normal renal function (CrCl[ 80 mL/min), mild RI
(CrCl 50–80 mL/min), moderate RI (CrCl 30 to\50 mL/
min), severe RI (CrCl\ 30 mL/min), and end-stage renal
disease (ESRD) requiring dialysis. The mean age of each
renal function group (50–68 years) was within the range
for target patient populations. All participants received
single 25-mg lenalidomide doses regardless of renal func-
tion. Mean urinary excretion of unchanged lenalidomide
was 84 % of the dose in the normal renal function group
and declined to 69, 38, and 43 % in the mild, moderate, and
severe RI groups, respectively. With diminishing renal
function, total and renal clearances of lenalidomide
decreased, while AUC and terminal half-life in plasma
increased. The differences in these parameters between
normal renal function and mild RI groups (\32 %) were
not statistically significant. In the moderate and severe RI
groups, AUC was increased by 200–300 %, and half-life
was prolonged to approximately 9–10 h. On a non-dialysis
day, patients with ESRD had an approximate 400 %
increase in AUC, with a long half-life of approximately
16 h. A 4-h hemodialysis session removed 31 % of
lenalidomide from the body. However, RI did not alter the
absorption (as indicated by Cmax and Tmax), protein bind-
ing, chiral inversion, or non-renal elimination of lenalido-
mide. From these findings, adjustments of the lenalidomide
starting dose are recommended for patients with
CrCl\ 50 mL/min [30].
RI is a common complication in MM, occurring in up to
half of patients and at various stages of the disease [45]. To
further assess whether the condition of MM may affect
lenalidomide exposure, a phase II study was prospectively
conducted and validated lenalidomide dose adjustments by
evaluating the pharmacokinetics, safety, and efficacy of
lenalidomide given with dexamethasone 40 mg weekly in
patients with MM and various degrees of stable RI [46]. The
study enrolled 38 patients (median age 65 years) with symp-
tomatic MM. These patients were stratified into the same five
groups as defined by the study above [30], but the stratification
was based on CrCl estimated using the Cockcroft–Gault for-
mula. The lenalidomide starting dose followed the dosing
guidelines derived in that study [30]: 25 mg once daily for
normal renal function and mild RI, 10 mg once daily for
moderate RI, 15 mg once every other day for severe RI, and
Table 2 Plasma pharmacokinetic parameters of lenalidomide in patients with various hematologic malignancies
MM (CrCl C 60 mL/min) MDS MCLa CLL AML ATL/PTCL
Caucasian Japanese Chinese Americans Japanese Americans Americans Americans Japanese
Dose (mg) 25 25 25 10 10 25 5 50 25
N 34 12 9 12 6 24 11 10 9
Tmax (h) 1 1 0.93 1 2.52 NA 1 1.91 1.48
Cmax (ng/mL) 487 572 596 179 136 440 85 946 503
AUC (h ng/mL)b 2124 2305 2202 933 867 2538 414 5509 2472
CL/F (mL/min) 196 181 184 179a 190 156 201 168 168
Vz/F (L) 54 42 51 58
a 54a 46 59 54c 47
t (h) 3.2 2.7 3.2 3.7
a 3.3 3.4 3.4 4.1 3.2
References [36] [36] [36] [29, 37] [38] [39] [40] [41] [42]
Data are expressed as median or arithmetic mean for Tmax and arithmetic or geometric mean for the remaining pharmacokinetic parameters
AML acute myeloid leukemia, ATL adult T-cell leukemia/lymphoma, AUC area under the plasma concentration–time curve, AUC24 AUC from
time zero to 24 h, AUC? AUC from time zero to infinity, CL/F apparent total clearance, CLL chronic lymphocytic leukemia, Cmax maximum
concentration, CrCl creatinine clearance, MCL mantle cell lymphoma, MDS myelodysplastic syndromes, MM multiple myeloma, NA not
available, PTCL peripheral T-cell lymphoma, t terminal half-life, Tmax time to reach Cmax, Vz/F apparent volume of distribution based on the
terminal phase
a Data were collected from the referenced study and are on file
b AUC? or AUC24. Values for the two parameters are expected to be similar due to the short half-life of the drug
c Derived from CL/F and t
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5 mg once daily for ESRD. The study showed a highly sig-
nificant linear relationship between lenalidomide clearance
and CrCl in patients with MM [46]. This relationship was
almost identical to that observed in patients with RI due to
non-malignant conditions (Fig. 2). Thus, MM disease itself
does not affect the relationship between lenalidomide clear-
ance (or plasma exposure) and renal function [46]. The mean
AUC of each renal function group was within ±25 % of the
mean AUC at the maximum tolerated dose [30], suggesting
that the starting doses achieved the appropriate plasma
exposure. Moreover, similar safety and efficacy were
observed across the renal function groups.
In agreement with the results above, a population phar-
macokinetic analysis showed that renal function was the only
clinically important intrinsic factor affecting lenalidomide
clearance, explaining 55 % of the interindividual variability
[39]. There was no difference in lenalidomide clearance
among patients with MM, MDS, and MCL, suggesting that
the same starting dose adjustment ratio can be applied to all
approved hematologic indications.
5.2 Patients with Hepatic Impairment
No formal studies have been conducted to assess the effect
of hepatic impairment on lenalidomide pharmacokinetics.
Since lenalidomide is minimally metabolized in liver,
lenalidomide plasma exposure is not anticipated to be
changed in patients with compromised liver function. In the
population pharmacokinetic analysis described above, mild
hepatic impairment (N = 16) did not influence lenalido-
mide clearance [39].
5.3 Pediatric Patients
The pharmacokinetics of lenalidomide have been evaluated
in pediatric patients with solid tumors in two phase I
studies [47, 48], including a total of 47 pediatric patients
aged 1–21 years. Doses studied were 15–116 mg/m2/day
for children with brain tumors [48], and 15–70 mg/m2/day
for children with other solid tumors [47]. Overall, there
was no large difference in pharmacokinetics between
pediatric (all ages combined) and adult patients (Table 3).
The half-life of lenalidomide was approximately 3 h in
pediatric patients [47, 48], which is similar to that observed
in adult patients with solid tumors [49, 50]. The maximum
tolerated dose was not defined in the two pediatric studies
because all doses evaluated were well tolerated during the
dose-finding period.
A comparison of lenalidomide clearance among pedi-
atric age groups showed that the body surface area-adjusted
lenalidomide clearance was significantly higher in children
5–11 years of age (160 ± 40 mL/min/m2) than in groups
12–17 years of age (120 ± 40 mL/min/m2) or 18–21 years
of age (105 ± 40 mL/min/m2) [47]. Thus, the body surface
area-based dose may lead to lower lenalidomide AUC in
children 5–11 years of age. Little pharmacokinetic infor-
mation is available for children younger than 5 years of
age. Because renal function reaches the adult level by
2 years of age [51], lenalidomide clearance in children C2
years of age is not anticipated to be highly different from
that in adults.
5.4 Ethnic Groups
A low sensitivity to ethnic factors has been demonstrated
for lenalidomide pharmacokinetics. In a comparative
pharmacokinetic study, Cmax and AUC increased in a dose-
proportional manner (5–20 mg) similarly for healthy
Caucasian and Japanese volunteers, and the enantiomeric
ratio of lenalidomide in plasma was nearly identical
between the two ethnic groups [27]. Lenalidomide plasma
exposure was also confirmed to be similar between Cau-
casian and Asian patients (Table 2), even though Asian
patients usually had a lower body weight [36]. Together
these findings demonstrate that no dose adjustment of
lenalidomide is necessary when Asian patients are treated.
6 Pharmacodynamics and Exposure Response
6.1 Effect on Cardiac Repolarization
An assessment of the effect of lenalidomide on corrected
QT (QTc) intervals was conducted in healthy males who



























90% Prediction band, noncancer
Best fit, noncancer
Fig. 2 Relationship between lenalidomide clearance and creatinine
clearance. Creatinine clearance was estimated using the Cockcroft–
Gault formula. The solid line indicates the best fit line of linear
regression, and the interval between the two dotted lines indicates the
90 % prediction interval of the best fit line for patients without
cancer. MM multiple myeloma. Based on data from the literature
reviewed in the text [30, 46]
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50 mg lenalidomide, 400 mg moxifloxacin (positive con-
trol), and placebo, in a randomized order [29]. Moxi-
floxacin significantly prolonged QTc, as expected. For
lenalidomide 10 and 50 mg, the time-matched changes
from placebo in the baseline-adjusted least-squares mean
QTc were \3 ms, and the upper limit of the two-sided
90 % CI for the change at all timepoints was\10 ms. After
lenalidomide administration, no subject experienced a
change from baseline [60 ms or QTc [450 ms. Due to
these outcomes, the study met the International Conference
on Harmonisation (ICH) E14 definition of a negative
thorough QT study.
Lenalidomide concentrations up to 1522 ng/mL were
not significantly associated with QTc changes [29]. The
lenalidomide concentration range observed in the QT study
was close to that observed in patients receiving lenalido-
mide doses up to 50 mg, including those with reduced drug
clearance associated with RI. Thus, lenalidomide is not
expected to prolong QTc intervals in patients receiving
therapeutic doses.
6.2 Exposure Response
The relationship between lenalidomide plasma exposure
and hematologic toxicities was first explored in patients
with transfusion-dependent MDS who were treated with
lenalidomide at 10 mg once daily [37]. Lenalidomide AUC
was significantly higher in patients who had a 50 %
reduction in neutrophil or platelet counts, and in patients
who developed grade 3/4 neutropenia or thrombocytopenia
within the first 28 days. Similar relationships were
observed with Cmax, but to a lesser degree. In addition,
patients with deletion 5q MDS had a greater decrease in
platelet and neutrophil counts than those without deletion
5q, even though there was no difference in lenalidomide
exposure between the two groups.
Subsequently, the relationship between lenalidomide
AUC and grade 3/4 neutropenia or thrombocytopenia was
examined in a meta-analysis including patients with MM,
MDS, or MCL from six clinical studies over the dose range
5–50 mg [39]. After adjusting for disease and baseline cell
counts, and including all treatment cycles up to 1 year,
lenalidomide AUC was a significant predictor of grade 3/4
thrombocytopenia (odds ratio [OR] 3.337, 95 % CI
1.183–9.415) and was also associated with increased grade
3/4 neutropenia (OR 1.978, 95 % CI 0.999–3.917). These
relationships were not apparent during the first treatment
cycle.
Furthermore, the impact of Cmax on safety and efficacy
was examined using data collected from patients with MM
and various degrees of renal function at the recommended
starting doses (5–25 mg) [46]. Because RI mainly increa-
ses AUC with limited effect on Cmax [30], a reduction in
lenalidomide starting dose to match AUC led to lower
Cmax, especially in patients with moderate RI and ESRD in
whom the dose was reduced by 60–80 % [46]. As such,
Cmax varied in a wider range than AUC in this study.
However, no apparent pattern was observed between
lenalidomide Cmax and the grade of hematologic AEs or
efficacy [46]. These data suggest that a high Cmax is not
critical for efficacy and support the AUC-matched dose
adjustment for patients with RI.
Table 3 Comparison of
lenalidomide pharmacokinetics
between adult and pediatric
patients with solid tumors
Solid tumors Central nervous system tumors
Adults Pediatric Adults Pediatrica
Dose range 5–40 mg 5–70 mg/m2 2.5–20 mg/m2 20–116 mg/m2
N 43 29 24 18
Age (years) 68 (24–89) 16 (1–21) 48 (20–82) 10 (3–22)
Tmax (h) 0.75–2 0.5–1.5 0.5–1.5 2–4
CL/F (mL/min/m2) 68–224b 100–202 169–451 122–234
Vz/F (L/m
2) 33.5–63b 21–31 39–90 27.4–60c
t (h) 2.7–6.7 1.4–3.1 2.2–5.6 2.6–3.3
References [50] [47] [49] [48]
Data are expressed as median (range) for age and arithmetic mean for pharmacokinetic parameters, unless
otherwise stated
CL/F apparent total clearance, t terminal half-life, Tmax time to reach the maximum concentration, Vz/F
apparent volume of distribution based on the terminal phase
a Pharmacokinetic parameters are expressed as median values. Cohorts with a sample size\3 are com-
bined to obtain the median value
b Assume a body surface area of 1.73 m2 for adult patients
c Derived from CL/F and t
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7 Drug–Drug Interactions
7.1 Metabolism-Based Drug–Drug Interactions
7.1.1 Potential of Drug–Drug Interactions via Metabolic
Pathways
Phase I or II metabolism did not occur when lenalidomide
was incubated with human liver microsomes, recombinant
CYP isozymes, and human hepatocytes [32]. Lenalido-
mide, at concentrations (C10 lM) far exceeding the ther-
apeutic Cmax (often \2 lM [30]), did not inhibit CYP
isozymes (1A2, 2C9, 2C19, 2E1, 2D6, 3A4/5) in human
liver microsomes and did not induce activity of CYP iso-
zymes (1A2, 2B6, 2C9, 2C19, 3A4/5) in cultured human
hepatocytes [32]. Hence, lenalidomide is not anticipated to
be subjected to pharmacokinetic drug–drug interactions
when coadministered with CYP inhibitors, inducers, or
substrates.
In a separate study, lenalidomide up to 50 lM did not
inhibit bilirubin glucuronidation in human liver micro-
somes with uridine diphosphate glucuronosyltransferase
1A1 (UGT1A1) genotyped as UGT1A1*1/*1, UGT1A1*1/
*28, and UGT1A1*28/*28 [52]. As such, UGT1A1 inhi-
bition and impairment of bilirubin conjugation may not be
the mechanism of the reported hyperbilirubinemia in
patients receiving lenalidomide [52, 53].
7.1.2 Dexamethasone
In patients with MM receiving lenalidomide/dexametha-
sone combination therapy, dexamethasone is administered
at 40 mg either weekly or more frequently (days 1–4, 9–12,
and 17–20 of a 28-day cycle) [23]. Dexamethasone is a
substrate and a weak-to-moderate inducer of CYP3A4
[54, 55]. Results from three within-patient comparison
studies demonstrated that dexamethasone has no effect on
lenalidomide pharmacokinetics. In the first study [35],
plasma exposure to lenalidomide (25 mg) on day 12 after
multiple coadministrations of dexamethasone (40 mg/day
on days 3–4 and 9–12) was similar to that observed on day
1 after lenalidomide alone, but the sample size was smaller
(N = 6). A second study [36] included more patients
(N = 11) and compared lenalidomide pharmacokinetics at
steady state with and without dexamethasone (40 mg). The
90 % CI for the ratio of treatment mean AUC or Cmax was
within the 80–125 % range (Fig. 3a), confirming the
absence of a clinically significant dexamethasone effect. A
third study was conducted in patients with RI [46], and no
difference was found in mean lenalidomide plasma con-
centrations at 2 h postdose (near Tmax) between the days
with or without 40 mg dexamethasone across the renal
function groups.
Dexamethasone is known to induce CYP3A4 activity at
high doses [55], thereby accelerating its own metabolism.
This may explain a slight reduction in dexamethasone
plasma AUC (-24 %) upon coadministration of lenalido-
mide with frequent high doses of dexamethasone [35].
7.1.3 Enzyme-Inducing Antiepileptic Drugs
In patients with recurrent primary CNS tumors, enzyme-
inducing antiepileptic drugs—known to induce CYP
enzymes such as CYP3A4—did not have any evident effect
on lenalidomide exposure [49].
7.1.4 Warfarin
Warfarin is an anticoagulant and is metabolized primarily
by CYP2C9, with some contribution from CYP2C19 and
CYP3A4 [56]. Patients with MM receiving lenalidomide
plus dexamethasone have an increased risk of venous
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Fig. 3 a Effect of food and
interacting drugs on plasma
exposure to lenalidomide, and
b effect of lenalidomide on
plasma exposure to interacting
drugs. Circles represent AUCt,
and squares represent Cmax.
Horizontal bars represent 90 %
CI for the percentage treatment
ratio. AUCt area under the
concentration–time curve from
time zero to the last quantifiable
concentration, Cmax maximum
concentration, CI confidence
interval. Based on data from the
literature reviewed in the text
[27, 33, 36, 59]
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thromboembolism; thus, antithrombotic prophylaxis is
recommended [22, 57]. Because of the prophylactic use of
warfarin, a drug with a narrow therapeutic index [58], in
patients with MM treated with lenalidomide, a double-
blind, placebo-controlled, randomized, crossover study was
conducted in healthy volunteers to evaluate the pharma-
cokinetic and pharmacodynamic interactions between
lenalidomide and warfarin [59]. In this study, coadminis-
tration of lenalidomide (10 mg) with warfarin (25 mg) did
not alter the plasma exposure to warfarin or lenalidomide
(Fig. 3). The effect of warfarin on prothrombin time and
international normalized ratio was also unchanged by
coadministration of lenalidomide. These data suggest that
warfarin and lenalidomide can be coadministered without
dose adjustments.
7.2 Transporter-Based Drug–Drug Interactions
7.2.1 Potential of Drug–Drug Interactions via Transport
Pathways
In cells or vesicles expressing human transporters,
lenalidomide was not a substrate of human breast cancer
resistance protein (BCRP); multidrug resistance protein
(MRP) transporter 1, MRP2, or MRP3; organic anion
transporters (OAT) 1 and OAT3; organic anion transporting
polypeptide (OATP) 1B1; organic cation transporters (OCT)
1 and OCT2; multidrug and toxin extrusion protein 1; and
OCT novel (OCTN) 1 and OCTN2 [52]. Lenalidomide, at a
concentrationC20 lM, did not inhibit transporting activities
of human BCRP, MRP2, OAT1, OAT3, OATP1B1,
OATP1B3, OCT2, or bile-salt export pump [52]. Hence,
lenalidomide is not anticipated to be subjected to pharma-
cokinetic drug–drug interactions when coadministered with
substrates and/or inhibitors of these transporters.
In monolayers of LLC-PK1 and MDCKII cell lines
expressing human P-glycoprotein (P-gp), lenalidomide was
shown to be transported with average efflux ratios of 3 and
3.66, respectively [52, 60]. The P-gp-mediated lenalido-
mide transport was concentration dependent, with a
Michaelis–Menten constant (Km) value of 802 ± 172 lM
[52]. The low efflux ratio and high Km value suggest that
lenalidomide is a weak P-gp substrate with low affinity for
P-gp. However, lenalidomide did not inhibit the P-gp-de-
pendent transport of digoxin at concentrations up to
300 lM [52]. From these findings, the potential of
lenalidomide interactions with P-gp substrates or inhibitors
is considered low.
7.2.2 P-Glycoprotein Inhibitors and/or Substrates
P-gp is extensively expressed in the luminal membrane of
the small intestine, where it pumps drugs back into the
intestinal lumen, and in the apical membrane of the kidney
proximal tubules, where it pumps drugs from tubule cells
into the tubular lumen [61]. Since lenalidomide is a weak
substrate of P-gp, P-gp inhibition could theoretically affect
oral absorption and renal excretion of lenalidomide. As
such, P-gp-based drug–drug interactions were suspected to
be a potential mechanism for increased lenalidomide
exposure upon coadministration of drugs interacting with
P-gp in patients with MM [60, 62, 63]. In an uncontrolled
dose-ranging study, mean Cmax and AUC of lenalidomide
(25 mg/day) were doubled with a dose increase of the P-gp
inhibitor/substrate temsirolimus from 15 to 20 mg/day,
while similar increases in Cmax and AUC of temsirolimus
(15 mg/day) were also observed with a dose increase of
lenalidomide from 20 to 25 mg/day [60]. In a within-pa-
tient comparison study, an increase in mean lenalidomide
blood concentration was observed at 2–4 h postdose when
lenalidomide (15 mg/day) was coadministered with the
P-gp inhibitor clarithromycin (400 mg twice daily) [62]. In
a case report, the lenalidomide AUC was 12-fold higher in
an MM patient receiving both lenalidomide (10 mg/day)
and the P-gp inhibitor itraconazole (100 mg/day) compared
with the AUC observed in other patients with MM
receiving lenalidomide (25 mg/day) alone [63]. Investiga-
tors in these studies suspected that oral absorption and/or
renal excretion of lenalidomide (and temsirolimus) could
be affected by drug interactions at the P-gp level
[60, 62, 63]. However, none of the three studies showed a
prolongation of drug half-life by the coadministration, and
clarithromycin did not increase trough concentration and
AUC of lenalidomide [62], which provides evidence
against an effect on drug elimination (i.e. renal excretion).
Lenalidomide is known to have high bioavailability
([90 %), which leaves little room (10 %) to increase oral
absorption by P-gp inhibition.
The results from the above studies were likely con-
founded by a lack of control [60], small sample size
[60, 63], multiple comorbidities, use of multiple con-
comitant medications, and other factors (e.g. food effect,
bioanalytical assay). Hence, controlled crossover clinical
studies [33] were conducted in healthy volunteers to
definitively evaluate pharmacokinetic interactions between
lenalidomide and three P-gp probe drugs, including the
prototypical P-gp substrate digoxin [64], the well-charac-
terized strong in vivo P-gp inhibitor quinidine [64], and the
P-gp inhibitor/substrate temsirolimus. In these studies,
digoxin (0.5 mg, single dose), quinidine (300–600 mg
twice daily for 5 days), or temsirolimus (25 mg, single
dose) had no effect on lenalidomide pharmacokinetics.
Mean treatment ratios and their 90 % CIs for Cmax and
AUC of lenalidomide all fell entirely within the conven-
tional bioequivalence range of 80–125 % (Fig. 3a). The
rate and capacity of lenalidomide renal excretion was not
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changed by quinidine or temsirolimus [33]. Oral absorption
of lenalidomide was also not altered by quinidine or tem-
sirolimus, judged from no change in Tmax, Cmax, and the
amount of lenalidomide excreted in urine. On the other
hand, lenalidomide had no effect on blood Cmax and AUC
of temsirolimus and its active metabolite sirolimus (also a
P-gp inhibitor/substrate) [Fig. 3b]. When administered
with lenalidomide versus placebo, the Cmax of digoxin was
slightly higher (?14 %), but there were no other effects on
digoxin pharmacokinetics [33]. From the controlled stud-
ies, it was concluded that no clinically significant phar-
macokinetic interactions exist between lenalidomide and a
P-gp inhibitor or substrate.
8 Discussion
The clinical pharmacokinetics of lenalidomide are char-
acterized by rapid absorption with high oral bioavailability,
a dose-proportional increase in plasma exposure, low pro-
tein binding, distribution into semen, minimum metabo-
lism, rapid elimination predominantly through urinary
excretion of the unchanged drug, and low ethnic sensitiv-
ity. Lenalidomide does not prolong QT interval at a dose
twice the approved maximum dose. Higher plasma expo-
sure to lenalidomide is associated with an increased risk of
neutropenia and thrombocytopenia. However, the increased
plasma exposure to lenalidomide in patients versus young,
healthy volunteers is considered clinically irrelevant
because the therapeutic doses are established based on
safety and efficacy data from these patients.
Coadministration with food reduces the extent and rate
of lenalidomide absorption. The reductions in AUC (-
20 %) and Cmax (-50 %) are considered clinically
insignificant because the concentration fluctuation during
typical lenalidomide treatment (e.g. following dose
reductions due to AEs) often has a similar or greater effect
on lenalidomide plasma exposure compared with the food
effect. Importantly, the safety and efficacy of lenalidomide
were established in registration trials in which the drug was
administered without any specific instructions regarding
food intake [8–13]. Therefore, lenalidomide can be
administered with or without food. However, the food-in-
duced reduction in lenalidomide Cmax may confound
pharmacokinetic data interpretation. Thus, it is preferred to
control food intake for pharmacokinetic evaluations,
especially for drug–drug interaction studies.
Since it is not a substrate, inhibitor, and/or inducer of
major human metabolic enzymes or transporters [32, 52],
lenalidomide has a low potential for pharmacokinetic drug
interactions. Although conflicting results were reported, no
clinically significant pharmacokinetic interactions between
lenalidomide and P-gp substrates/inhibitors were observed
in well-controlled studies [33]. Therefore, lenalidomide
can be coadministered with a P-gp inhibitor or substrate
without dose adjustment. It should be noted that the
underlying mechanism for a 14 % increase in digoxin Cmax
upon coadministration of lenalidomide cannot be explained
by direct inhibition of P-gp because lenalidomide does not
inhibit P-gp-dependent transport of digoxin in vitro [52].
To date, there has been no evidence in the literature of any
significant toxicity due to concomitant use of lenalidomide
and digoxin. Because digoxin has a narrow therapeutic
window, periodic monitoring of digoxin concentration is
recommended during lenalidomide therapy.
The most important factor increasing lenalidomide
plasma exposure is RI [30]. A general guideline of starting
dose adjustments has been developed for patients with
CrCl\ 50 mL/min (Table 4) based on increased AUC by
RI, pharmacokinetic similarity across patient populations,
availability of the lenalidomide dosage strengths, dose
response for efficacy, and patients’ tolerability. The
50 mL/min CrCl cutoff was chosen because it was used as
the lower limit for mild RI (CrCl 50–80 mL/min) in two
definitive renal studies, and the increase in plasma expo-
sure with mild RI was modest [30, 46]. Furthermore, the
full starting dose was well tolerated in patients with mild
RI in clinical studies [46, 65, 66]. Hemodialysis accelerates
Table 4 Recommendations for the starting lenalidomide dose in patients with impaired renal function
Renal function (CrCl) Full starting dose 25 mg Full starting dose 10 mg
Moderate renal impairment (CrCl = 30 to
\50 mL/min)
10 mg once dailya 5 mg once daily
Severe renal impairment (CrCl\ 30 mL/min,
not requiring dialysis)
15 mg once every other day or 7.5 mg once
dailyb
5 mg once every other day or 2.5 mg dailyb
End-stage renal disease (CrCl\ 30 mL/min,
requiring dialysis)
5 mg once daily
On dialysis days, the dose should be
administered following dialysis
5 mg three times a week or 2.5 mg dailyb
On dialysis days, the dose should be
administered following dialysis
CrCl creatinine clearance
a The dose may be escalated to 15 mg once daily after two cycles if the patient is not responding to treatment and is tolerating the drug
b In countries where the 2.5- and/or 7.5-mg capsule strengths are available
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lenalidomide removal from the body [30]. Thus, in patients
with ESRD, the reduced dose should be administered
immediately following completion of each dialysis session
to minimize the effect of hemodialysis on lenalidomide
clearance.
The aim of dose adjustment in patients with
CrCl\ 50 mL/min is to achieve an initial AUC that would
be efficacious with a manageable AE profile, i.e. close to
the AUC range after administration of the full starting dose
to patients with CrCl C 50 mL/min. Simulation results
suggest that the steady-state daily AUC at the reduced
starting dose for patients with moderate or worse RI is
comparable with that at the full starting dose for patients
with CrCl C 50 mL/min (Fig. 4a, b). Because early
lenalidomide dose intensity is considered crucial for opti-
mal outcomes [67], a modestly high starting AUC is pre-
ferred over a lower AUC when a desirable AUC match is
not feasible. Depending on indication and the availability
of capsule strengths, there are two dosing schedules for the
reduced starting dose in patients with severe RI or ESRD:
once daily with lower capsule strengths, or less frequent
dosing (once every other day or three times a week) with
higher capsule strengths. The average daily AUC is pre-
dicted to be similar for the two schedules (Fig. 4a, b).
Compared with the once every other day or three times a
week regimen, the once daily regimen would reduce the
fluctuation of lenalidomide plasma level (Fig. 4c–e) and
the individual body load of each single dose, which may
reduce toxicity. The once daily regimen may also improve
patient compliance in terms of allowing for daily dosing
where appropriate.
Lenalidomide has a short half-life and rarely accumu-
lates in plasma under a daily dosing schedule. The 88 %
recovery of total radioactivity of [14C]-lenalidomide from
excreta within 24 h [28] suggests little tissue retention of
lenalidomide and its metabolites. Thus, most lenalidomide
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Fig. 4 Predicted lenalidomide plasma exposure at steady state in
patients with RI. a Predicted average daily AUC at recommended
starting doses when the full starting dose is 25 mg for patients with
creatinine clearance C50 mL. b Predicted AUC at recommended
starting doses when the full starting dose is 10 mg for patients with
creatinine clearance C50 mL. c–e Comparison of predicted lenalido-
mide plasma concentration profiles among QD, QOD, and TIW
dosing schedules in patients with severe RI or ESRD. In a, b, the
horizontal dotted lines represent the 5th, 50th, and 95th percentiles of
AUC observed in target patient populations, the box plots represent
AUC predicted for each renal function group based on data from non-
cancer patients [30], the white line in each box represents the mean,
the height of each box corresponds to the interval between the first
and third quartiles, and the horizontal lines at two ends of each box
correspond to the range, from minimum to maximum. RI renal
impairment, AUC area under the concentration–time curve, QD once
daily, QOD once every other day, TIW three times a week, ESRD end-
stage renal disease. Data on file at Celgene
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toxicities can be managed effectively by dose reductions
and interruptions in subsequent treatment cycles if the
patient does not tolerate the starting dose.
9 Conclusions
The studies discussed in this review provide the pharma-
cokinetic and pharmacodynamic basis for safe and effec-
tive use of lenalidomide in the clinic. Renal function is the
most important factor affecting lenalidomide plasma
exposure in humans, and AUC-matched dose adjustments
are recommended for patients with CrCl\ 50 mL/min at
the start of therapy. Lenalidomide toxicities can be further
controlled by step-down dose reductions/interruptions. No
dose adjustment for lenalidomide is warranted on the basis
of age, ethnicity, mild hepatic impairment, or drug–drug
interactions.
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